Bruker (BRKR)
Maker of magnetic-resonance, mass-spectrometry, and X-ray instruments for scientific and industrial research.
Something off on this page? Send us feedback.
Builds precision instruments — magnetic-resonance and mass-spectrometry systems anchored by its timsTOF platform, plus X-ray, nano-surface, and superconducting-magnet tools — for research labs in academia, pharma, and industry. Recent acquisitions extend the business into molecular diagnostics and spatial biology, with most revenue generated outside the United States.
Makes precision scientific instruments for reading matter at the molecular and atomic level — magnetic-resonance systems, mass spectrometers built around the timsTOF platform, X-ray and nano-surface analysis tools, and superconducting magnets.
The business traces to 1960, when a physics professor in Karlsruhe, West Germany, began building nuclear-magnetic-resonance instruments that became its founding line.
Recent acquisitions have pushed the portfolio from instrument sales into molecular diagnostics and spatial biology, aiming instruments and testing at the same post-genomic research customers.
Customers are concentrated in academic, pharmaceutical, and industrial research labs, with most sales outside the United States. Research-funding cycles drive demand, and the founding Laukien family, led by the chairman and chief executive, remains its largest shareholder.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | UBS | Reiterate | Rating: —Target: $60 | Target: $65 |
| Aug 5, 2026 | Stifel Nicolaus | Target | Target: $45 | Target: $50 |
| Jun 29, 2026 | Guggenheim | Reiterate | Rating: —Target: $58 | Target: $70 |
| Jun 24, 2026 | UBS | Target | Target: $45 | Target: $60 |
| May 8, 2026 | Stifel Nicolaus | Target | Target: $40 | Target: $45 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $184.9M · Total debt $1.92B · Total assets $6.05B · Shareholders' equity $2.40B
- Revenue
- $838.5M
- Operating income
- −$65.3M
- Net income
- −$52.0M
HistoryDividendAnnual yield
| Institutions | 94.29% | 143.66M shares | |
|---|---|---|---|
| 432 holders · as of Jun 30, 2026 | |||
| Insiders | 30.78% | 46.89M shares | |
| 20 holders · as of Sep 16, 2026 | |||
| Adds to | 125.07% | ||
152.36M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 125.07%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Frank H. LaukienInsiderdirector, 10 percent owner, officer: PRESIDENT & CEO | 25.27% | 38.51M | filed Aug 18, 2026 |
FMR LLCInstitution | 13.28% | 20.24M | as of Jun 30, 2026 |
Orbis Allan Gray LtdInstitution | 11.77% | 17.94M | as of Jun 30, 2026 |
Orbis Investment Management LtdInstitution | 11.06% | 16.85M | filed May 15, 2026 |
BlackRock, Inc.Institution | 7.49% | 11.41M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 15, 2026 | Mark Munch | officer: EXEC VP&PRES BRUKER NANO INC. | −2,000 | $52.87 |
| Aug 14, 2026 | Mark Munch | officer: EXEC VP&PRES BRUKER NANO INC. | −2,000 | $57.60 |
| Aug 17, 2026 | Wolfgang Pusch | officer: President BMID Group | −3,473 | $56.90 |
| Jul 15, 2026 | Mark Munch | officer: EXEC VP&PRES BRUKER NANO INC. | −2,000 | $60.25 |
| Jun 15, 2026 | Mark Munch | officer: EXEC VP&PRES BRUKER NANO INC. | −2,000 | $54.76 |
- Thermo Fisher Scientific
Two-horse-race rival in proteomics MS; also X-ray and CALID overlap
- Danaher
Multi-front rival via SCIEX mass spec, Leica microscopy, and Cepheid MDx
- Agilent Technologies
CALID and NANO segment rival across LC-MS, GC-MS, and X-ray instruments
- Waters
Direct LC-MS rival, scaling up via pending BD Biosciences/Diagnostics deal
- 10x Genomics
Active spatial-biology rival; $68M patent settlement plus ongoing royalties
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Bruker | $60.82 | −0.64% | $9.32B | — | 26.8 | 2.7 | +5.2% |
| Thermo Fisher Scientific | $658.21 | −0.05% | $243.49B | 35.4 | 25.1 | 5.3 | +10.5% |
| Danaher | $220.57 | −0.24% | $155.44B | 39.3 | 24.9 | 6.2 | +5.5% |
| Agilent Technologies | $165.41 | −1.11% | $47.24B | 32.9 | 25.2 | 6.4 | +8.1% |
| Waters | $423.76 | −0.47% | $41.80B | 106.2 | 27.1 | 9.0 | +113.3% |
| 10x Genomics | $77.08 | −4.49% | $10.25B | — | — | 16.6 | −12.7% |
| Median | 37.3 | 25.2 | 6.4 | +8.1% |